Acadia Pharmaceuticals | ACAD - Ebitda

Aktienkurs
20.60
Täglich Wechseln
-0.39 -1.86%
Monatlich
-17.50%
Jährlich
20.40%
Q1 Prognose
20.12




Ebitda Veränderung Datum
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
ALKERMES USD 100.31M 21.24M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Cara Therapeutics USD -2.39M 3.16M 2025-03
Corcept Therapeutics USD 4.2M 6.5M 2025-12
Cytokinetics USD -277.18M 169.36M 2025-09
Eisai JPY 30.1B 6.62B 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
Incyte USD 414.5M 92.42M 2025-12
J&J USD 9.52B 389M 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Pfizer USD 6.08B 351M 2025-09
Prothena USD -39.53M 12.25M 2025-09
PTC Therapeutics USD 20.63M 53.74M 2025-09
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
Vanda Pharmaceuticals USD -8.31M 2.37M 2024-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09